Provided by Tiger Trade Technology Pte. Ltd.

CANSINOBIO

35.960
-2.040-5.37%
Volume:10.83M
Turnover:404.67M
Market Cap:8.88B
PE:279.33
High:39.680
Open:39.200
Low:35.740
Close:38.000
52wk High:52.200
52wk Low:19.220
Shares:247.04M
HK Float Shares:132.67M
Volume Ratio:2.03
T/O Rate:8.16%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.129
ROE:0.82%
ROA:-0.80%
PB:1.52
PE(LYR):279.33
PS:6.14

Loading ...

CansinoBIO Secures Regulatory Approval in Argentina for Meningococcal Vaccine

Stock News
·
Jun 25

CanSino Biologics Defines Governance, Capital Structure and Dividend Policy in Updated Articles of Association

Bulletin Express
·
Jun 10

CANSINOBIO Keeps Share Capital Steady in May; 2.91 Million Shares Reserved for Incentive Plans

Bulletin Express
·
Jun 02

CanSino Biologics Begins Trials of Broad Pneumococcal Conjugate Vaccine

MT Newswires Live
·
May 26

CANSINOBIO (06185) Initiates Phase I/II Clinical Trial for PCV24 with First Participant Enrolled

Stock News
·
May 26

CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient

Bulletin Express
·
May 26

CANSINOBIO Sets 2025 AGM for 10 June 2026; Seeks Share-Issuance, Repurchase and Dividend Mandates

Bulletin Express
·
May 19

CANSINOBIO Calls 10 June 2026 AGM to Approve 2025 Results, No Dividend Payout, and Fresh Financing Mandates

Bulletin Express
·
May 19

CanSino Biologics' Drug Application for Combined Vaccines Granted Priority Review in China

MT Newswires Live
·
May 11

CansinoBIO's Td5cp Vaccine for Adolescents and Adults Granted Priority Review by China's Drug Regulator

Stock News
·
May 11

CanSino Biologics Q1 Loss After Two Profitable Quarters Tests Bullish Profitability Narratives

Simply Wall St.
·
Apr 30

UBS Lowers CANSINOBIO (06185) Target Price to HK$52.4, Q1 Results In Line

Stock News
·
Apr 30

CanSinoBIO Proposes Comprehensive Amendments to Articles and Board Procedures to Strengthen Governance

Bulletin Express
·
Apr 28

CANSINOBIO Reports Widened Net Loss in Q1

Stock News
·
Apr 28

康希诺生物2025年业绩扭亏为盈,核心疫苗销售推动营收突破10.59亿元

Bulletin Express
·
Apr 22

CANSINOBIO 2025 ESG Report: GHG Intensity Cut 17.39%, RMB 371 Million R&D Outlay and Multiple Vaccine Milestones

Bulletin Express
·
Apr 22

CanSinoBIO reiterates switch to electronic corporate communications, requests shareholders’ email registration

Bulletin Express
·
Apr 22

CANSINOBIO Schedules 28 April Board Meeting to Approve Q1 2026 Results

Bulletin Express
·
Apr 16

CanSino Biologics Infant Combination Vaccine Approved in China

MT Newswires Live
·
Apr 13

Hong Kong Grants First Stablecoin Issuer Licenses as Iran-US Talks Show Major Rifts

Stock News
·
Apr 13